How to buy Black Diamond Therapeutics stock

Black Diamond Therapeutics, Inc is a biotechnology business based in the US. Black Diamond Therapeutics shares (BDTX) are listed on the NASDAQ and all prices are listed in US Dollars. Black Diamond Therapeutics employs 69 staff and has a market cap (total outstanding shares value) of 0.00.

Black Diamond Therapeutics share price

Use our graph to track the performance of BDTX stocks over time.

Black Diamond Therapeutics shares at a glance

• Key figures

Information last updated 2021-04-29.

52-week range	$21.04 - $45.97
50-day moving average	$25.12
200-day moving average	$29.25
Wall St. target price	$52.20
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.08

Buy Black Diamond Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Black Diamond Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Black Diamond Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Black Diamond Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-17.82%
Return on equity TTM	-29.17%
Profit margin	0%
Book value	N/A
Market capitalisation	$1 billion

TTM: trailing 12 months

Shorting Black Diamond Therapeutics shares

There are currently 4.7 million Black Diamond Therapeutics shares held short by investors – that's known as Black Diamond Therapeutics's "short interest". This figure is 1% up from 4.6 million last month.

There are a few different ways that this level of interest in shorting Black Diamond Therapeutics shares can be evaluated.

Black Diamond Therapeutics's "short interest ratio" (SIR)

Black Diamond Therapeutics's "short interest ratio" (SIR) is the quantity of Black Diamond Therapeutics shares currently shorted divided by the average quantity of Black Diamond Therapeutics shares traded daily (recently around 433922.40740741). Black Diamond Therapeutics's SIR currently stands at 10.8. In other words for every 100,000 Black Diamond Therapeutics shares traded daily on the market, roughly 10800 shares are currently held short.

However Black Diamond Therapeutics's short interest can also be evaluated against the total number of Black Diamond Therapeutics shares, or, against the total number of tradable Black Diamond Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Black Diamond Therapeutics's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Black Diamond Therapeutics shares in existence, roughly 130 shares are currently held short) or 0.1938% of the tradable shares (for every 100,000 tradable Black Diamond Therapeutics shares, roughly 194 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Black Diamond Therapeutics.

Find out more about how you can short Black Diamond Therapeutics stock.

Black Diamond Therapeutics share dividends

We're not expecting Black Diamond Therapeutics to pay a dividend over the next 12 months.

Black Diamond Therapeutics overview

Black Diamond Therapeutics, Inc. , a biotechnology company, discover and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an irreversible small molecule inhibitor that is designed to block the function of family of oncogenic proteins defined by driver mutations across a range of tumor types, and which affect the epidermal growth factor receptor (EGFR), the tyrosine-protein kinase, or human epidermal growth factor receptor 2. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including allosteric and canonical EGFR mutations; and various early stage pipeline programs of allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018.

Frequently asked questions

• What percentage of Black Diamond Therapeutics is owned by insiders or institutions?

  Currently 3.189% of Black Diamond Therapeutics shares are held by insiders and 101.401% by institutions.

• How many people work for Black Diamond Therapeutics?

  Latest data suggests 69 work at Black Diamond Therapeutics.

• When does the fiscal year end for Black Diamond Therapeutics?

  Black Diamond Therapeutics's fiscal year ends in December.

• Where is Black Diamond Therapeutics based?

  Black Diamond Therapeutics's address is: One Main Street, Cambridge, MA, United States, 02142

• What is Black Diamond Therapeutics's ISIN number?

  Black Diamond Therapeutics's international securities identification number is: US09203E1055

• What is Black Diamond Therapeutics's CUSIP number?

  Black Diamond Therapeutics's Committee on Uniform Securities Identification Procedures number is: 09203E105